A Model for the Assessment of Human Recombinant Interleukin 2 (RIL2) Coated Erythrocytes as a Delivery System for Immunotherapy
A carrier system for IL2 is needed in order to circumvent the toxicity associated with high dose interleukin 2 (IL2) administration and its rapid clearance from circulation. Erythrocytes (RBC) coated with recombinant interleukin 2 (rIL2) provide a means of delivering IL2 into the system in a continuous, low dose manner which in turn maintains a low, potentially non-toxic, IL2 concentration. Murine RBC coated with rIL2 (RBC-rIL2) induce cytotoxicity (21–31%) upon cytotoxic testing of spleens cells stimulated in vivo. Using the murine Meth A sarcoma model, the effectiveness of this RBC-rIL2 vehicle is demonstrated in vivo by a 84% reduction in tumor size as compared to the soluble rIL2 treated mice. Moreover, the RBC-rIL2 vehicle is able to induce tumoricidal cytotoxicity with very low rIL2 concentrations (about 10,000 I.U. of rIL2 per mouse). These results indicate that rIL2 retains its biological activity when bound to the RBC and therefore could prove useful as a therapeutic delivery system for cancer treatment.
KeywordsSpleen Cell Tumor Bearing Mouse Capillary Leak Syndrome CTLL Cell Interferon Gamma Production
Unable to display preview. Download preview PDF.
- Anstee D.J., Gardner B., Spring F.A., Holmes C.H., Simpson K.L., Parsons S.F., Mallinson G., Yousaf S.M., Judson P.A. (1991) New monoclonal antibodies in CD44 and CD58: their use to quantify CD44 and CD58 on normal human erythrocytes and to compare the distribution of CD44 and CD58 in human tissues. Immunol 74(2), 197–205.Google Scholar
- DeLoach J.R., Andrews K., Sheffield C.L. (1988) Encapsulation of interleukin-2 in murine erythrocytes and subsequent deposition in mice receiving a subcutaneous injection. Biotech Appl Biochem 10, 183–190.Google Scholar
- Mier J.W., Vachino G., Klempner M.S., Aronson F.R., Noring R., Smith S., Brandon E.R, Laird W., Atkins M.B. (1990) Inhibition of interleukin 2 induced tumor necrosis factor release by defect and differential suppression of interleukin 2 associated side effects. Blood 76, 1933–1940.PubMedGoogle Scholar
- Ropars C, Chassaigne M., Nicolau C. (1987) Resealed Erythrocyte as Carriers and Bioreactors. in Adv Biosciences vol. 67 Pergamon Press, Oxford.Google Scholar
- Rosenberg S.A., Lotze M.T., Muul L.M., Chang A.E., Avis F.P., Leitman S., Linehan W.M., Robertson C.N., Lee R.E., Rubin J.T., Seipp CA., Simpson CG., White D.E. (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin 2 alone. N Eng J Med 316, 889–905.CrossRefGoogle Scholar
- Sosman J.A., Weiss G.R., Margolin K.A., Aronson F.R., Sznol M., Atkins M.B., O’Boyle K., Fisher S.G., Mier J., Vachino G., Caliendo G. (1993) Phase I B clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunological effects. J Clin Oncol 11, 1496–1505.PubMedGoogle Scholar
- Thrombe P.S., Deodhar S.D. (1984) Inhibition of liver metastases in murine colon adenocarcinoma by liposomes containing human c-reactive protein or crude lymphokine. Cancer Immunol Immunother 16, 145–150.Google Scholar
- Tuttle T.M., McCrady C.W., Inge T.H., Salour M., Bear H.D. (1992) ʳ-Interferon plays a key role in T cell induced tumor regression. Cancer Research 53, 833–839.Google Scholar
- Weigent D.A., Stanton G.J., Johnson H.M. (1983) Interleukin 2 enhances natural killer cell activity through induction of gamma interferon. Infect Imm 41, 992–997.32.Google Scholar